New T cell therapy for patients with relapsed acute myeloid leukemia after stem cell transplant
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
This study is testing a new T cell therapy called MT-401 for patients with relapsed acute myeloid leukemia (AML) who have had a stem cell transplant, to see if it can better target cancer cells while protecting healthy ones.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marker Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10901992 on NIH RePORTER |
What this research studies
This research focuses on a novel T cell therapy called MT-401, designed specifically for patients with relapsed acute myeloid leukemia (AML) who have undergone stem cell transplantation. The therapy utilizes T cells that target multiple tumor-associated antigens, which helps to minimize the chances of the cancer escaping treatment. Patients will receive this therapy following a bridging treatment with hypomethylating agents, aiming to enhance the effectiveness of the T cell response. The approach is based on previous findings that show promise in targeting AML cells while sparing healthy tissues.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have experienced a relapse of acute myeloid leukemia after receiving a stem cell transplant.
Not a fit: Patients who have not undergone stem cell transplantation or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with relapsed AML.
How similar studies have performed: Previous studies have shown that similar T cell therapies targeting multiple antigens have been clinically safe and effective in treating various cancers.
Where this research is happening
Houston, United States
- Marker Therapeutics, INC. — Houston, United States (Active)
Researchers
- Principal investigator: Vera, Juan Fernando — Marker Therapeutics, INC.
- Study coordinator: Vera, Juan Fernando
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.